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Abstract
Noninvasive imaging is a critical technology for diagnosis, classification, and subsequent treatment planning for patients with
glioblastoma. It has been shown that the EphA2 receptor tyrosine kinase (RTK) is overexpressed in a number of tumors, including
glioblastoma. Expression levels of Eph RTKs have been linked to tumor progression, metastatic spread, and poor patient prognosis. As
EphA2 is expressed at low levels in normal neural tissues, this protein represents an attractive imaging target for delineation of tumor
infiltration, providing an improved platform for image-guided therapy. In this study, EphA2-4B3, a monoclonal antibody specific to
human EphA2, was labeled with 64Cu through conjugation to the chelator 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA). The
resulting complex was used as a positron emission tomography (PET) tracer for the acquisition of high-resolution longitudinal PET/
magnetic resonance images. EphA2-4B3-NOTA-64Cu images were qualitatively and quantitatively compared to the current clinical
standards of [18F]FDOPA and gadolinium (Gd) contrast–enhanced MRI. We show that EphA2-4B3-NOTA-64Cu effectively delineates
tumor boundaries in three different mouse models of glioblastoma. Tumor to brain contrast is significantly higher in EphA2-4B3-
NOTA-64Cu images than in [18F]FDOPA images and Gd contrast–enhanced MRI. Furthermore, we show that nonspecific uptake in the
liver and spleen can be effectively blocked by a dose of nonspecific (isotype control) IgG.
N EUROIMAGING has evolved from being a purelyanatomic tool to a discipline that can offer anatomic,
functional, hemodynamic (physiologic), metabolic, and
molecular information.1–5 From the perspective of patients
with brain tumors, the use of neuroimaging techniques is an
essential stage in the diagnosis and classification of the
tumor and to assess patient response following treatment.6
Currently, a combination of magnetic resonance imaging
(MRI), computed tomography (CT), and positron emission
tomography (PET) techniques is used in the diagnosis and
treatment of glioblastoma. Despite the growing effectiveness
of these techniques, a number of key obstacles remain. For
11C- and some 18F-labeled amino acid–based oncology tra-
cers, a prerequisite for clinical diagnostics is ready access to a
cyclotron and radiopharmacy facilities. Longer half-life
radiometals such as 64Cu and 89Zr, along with the develop-
ment of bifunctional chelators for simple conjugation to
biomolecules, may provide a mechanism for more wide-
spread oncology PET imaging. However, for this scenario to
be a realistic alternative, the efficacy of new potential
imaging agents must be equal to or greater than currently
used 11C- or 18F-based tracers, such as [11C]methionine7 or
[18F]FDOPA.7–9 Over the past 20 years, the resurgence in
nuclear imaging techniques has been bolstered by significant
advances in the production and radiolabeling of highly
specific biomolecules such as monoclonal antibodies
(mAbs). Reproducible protocols for the large-scale produc-
tion of mAbs10 have enabled researchers to effectively target
an enormous number of receptors in a highly specific way.
The impact of this development on PET imaging has been
significant with increasing application of radiolabeled mAbs
as diagnostic and therapeutic targets in oncology.11–15
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The Eph receptor tyrosine kinases (RTKs) and their Eph-
interacting ligands (ephrins) are the largest subfamily of
tyrosine kinases, consisting of 16 Eph receptors and 9 ephrin
ligands.16 From the discovery of the first Eph RTK,17 evi-
dence has been accumulating to implicate the Eph family in
tumor development and progressionda body of work that
continues to grow. The complex bidirectional signaling
mechanisms between Eph RTKs and ephrin ligands have
been shown to influence cell morphology, adhesion,
migration, invasion, proliferation, and survival.16,18,19 As
such, many studies have linked Eph and ephrin expression
levels with tumor progression, metastatic spread, and patient
survival. In the specific case of EphA2, an increasing number
of studies have shown a correlation between EphA2
overexpression and poor patient prognosis.20–27 EphA2
overexpression has been observed in a number of
glioblastoma-derived cell lines,28–30 and levels of EphA2 are
significantly higher in glioblastoma tissue than in normal
brain tissue. A recent study by Day and colleagues showed
that EphA2 expression is significantly elevated (p = .021) in
high-grade glioma specimens (n = 54 patients) compared to
normal brain specimens (n = 11 patients).31 The over-
expression of Eph receptor tyrosine kinases, including
EphA2 in glioblastoma, has been indicated to be a critical
measure of invasiveness, and as such, Eph RTKs have
attracted attention as targets for the development of imaging
and therapeutic agents.30,32–34 The development of mole-
cular imaging agents specific to EphA2 is a logical precursor
to the development of therapeutics specific to EphA2. In this
way, potential patient-specific expression of the receptor can
be assessed before delivery of the targeted therapeutic.
Despite increasing attention as therapeutic targets and as
biomarkers for both diagnosis and prognosis in a number of
cancers, in vivo imaging of tumors using Eph receptors as
targets has only been reported in a small number of studies,
with no study to date having compared Eph-based imaging
to current “state of the art” clinical imaging methods, such
as [18F]FDOPA PET and contrast-enhanced MRI. Vearing
and colleagues showed that an 111In-labeled mAb specific to
EphA3 accumulated in xenograft tissue in a subcutaneous
HEK293 model to a level of 27 %ID/g 4 days postinjection.35
Imaging by gamma camera showed that the xenograft was
clearly visible up to 96 hours postinjection. Cai and collea-
gues evaluated a 64Cu-labeled mAb specific to EphA2 in
eight subcutaneous tumor models, including a U87 model of
glioblastoma.36 The authors found that tumor uptake as
measured by microPET imaging correlated well with EphA2
expression as measured by Western blot analysis. Xiong and
colleagues identified the potential of EphB4 as an imaging
target in prostate and colon cancer models.37 The authors
showed uptake of approximately 1 %ID/g in the tumor after
24 hours following injection of a 64Cu-labeled peptide spe-
cific to the EphB4 receptor. Zhang and colleagues investi-
gated the use of a polymeric micellar nanoparticle dual for
single-photon emission computed tomography (SPECT)/
optical imaging platforms targeted to EphB4 by conjugation
to a peptide.38 The authors showed high retention of the
imaging agent in the tumor and provided strong correlation
between in vivo SPECT/CTand fluorescence imaging and ex
vivo autoradiography and fluorescence imaging. More
recently, Mamat and colleagues reported the development of
a small molecule 18F-labeled tracer specific to EphB4.39 The
authors reported high metabolic stability of the tracer,
but autoradiography showed low uptake into EphB4-
overexpressing tumors. Although the initial efficacy of the
labeled mAb can be investigated in subcutaneous models of
glioblastoma, this experimental design removes the influ-
ence of the blood-brain barrier. As yet, the EphA2 RTK has
not been fully exploited as a target for PET tracers and has
not been investigated as an imaging target in an intracranial
model of glioblastoma.
The novel contribution of this work is the presentation of
biodistribution and pharmacokinetic data of a unique mAb
specific to the human form of EphA2 (4B3) in a U87
orthotopic mouse model and two unique patient-derived
orthotopic mouse models, RN1 and WK1. In addition, we
describe for the first time qualitative and quantitative
comparisons of tumor to brain contrast versus two clinical
standards: contrast-enhanced MRI and [18F]FDOPA PET.
Furthermore, we evaluate the use of a blocking dose of cold,
nonspecific mAb as a method of increasing blood half-life
and increasing specific tumor uptake.
Materials and Methods
Reagents
Chemical reagents were sourced from Sigma-Aldrich (St. Louis,
MO) and were used as received. 1,4,7-Triazacyclononane-1,4,7-
triacetic acid was purchased from Macrocylics (Dallas, TX),
and Amicon centrifugal filters were purchased from Sigma-
Aldrich. 64CuCl2 was produced by theDepartment ofMedical
Technology & Physics and RAPID PET Laboratories, Sir
Charles Gairdner Hospital (Perth, Western Australia). [18F]
FDOPA was produced by Queensland PET, Royal Brisbane
and Women’s Hospital (Brisbane, Queensland).
Antibodies
The EphA2-4B3 mAb is a human-specific IgG2a antibody
raised in wild-type mice against a human EphA2-Fc
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immunogen. It was produced by standard hybridoma
methodology in the laboratory of A. Boyd at QIMR Ber-
ghofer Medical Research Institute. Large-scale antibody
production and purification were carried out at the Protein
Expression Facility, Australian Institute for Bioengineering
and Nanotechnology, The University of Queensland
(Brisbane, Australia).
Tumor Models
Three glioblastoma tumor models were used in this
investigation:
U87 cells40 were maintained in RPMI160 medium
(Gibco) supplemented with 10% fetal bovine serum (Gibco),
2 mM L-glutamine, 25 mM HEPES, 25 mM sodium bicar-
bonate, 100 U/mL penicillin, and 100 mg/mL streptomycin.
Two early-passage glioblastoma cell lines, RN1 and WK1,
were used to develop further xenograft models. The RN1 cell
line was derived from a 56-year-old man with a left temporal
glioblastoma multiforme (glioblastoma, World Health
Organization grade IV) prior to him receiving chemother-
apy or radiotherapy. The primary tumor was classified as the
classic subtype of glioblastoma.41 The patient survived 243
days from the date of his diagnosis. The WK1 cell line was
derived from a 77-year-old man with a right parieto-
occipital glioblastoma, again prior to him receiving che-
motherapy or radiotherapy. The primary tumor belongs to
the mesenchymal subtype of glioblastoma.41 The patient
survived 121 days from the date of diagnosis.
Both cell lines were grown as an adherent culture in
Matrigel-coatedtissuecultureflasksinRHB-Astemcellculture
medium (StemCell Inc) containing 100 U/mL penicillin and
100 mg/mL streptomycin and supplemented with 20 ng/mL
epidermal growth factor and 10 ng/mL fibroblast growth
factor-basic (StemCell Inc, Newark, CA).42 Tumor tissue was
collected as part of a study approved by the human ethics
committees of the QIMR Berghofer Medical Research
Institute and the Royal Brisbane and Women’s Hospital,
with patient consent. The tumor was examined by a
neuropathologist to verify tumor type and grade.
All cells were cultured in 5% CO2/95% humidified air
atmosphere at 37C and used when they reached 70 to
80% confluence. Cells (100,000 in 2 mL of phosphate-
buffered saline [PBS]) were injected into the right striatum
of 6-week-old female NOD/SCID mice using a stereotaxic
frame under isoflurane anesthesia. Cells were injected at a
depth of 3 mm, 1.6 mm rostral and 0.8 mm lateral to the
bregma. Expression of EphA2 was measured by flow
cytometry in each cell line (see Figure S1, online version
only).
NOTA Conjugation
NOTA-NCS (100 mg) was dissolved in sodium carbonate
buffer (pH 9) and added to EphA2-4B3 (1 mL at 1 mg/mL)
in sodium carbonate buffer (pH 9). The resulting mixture
was gently agitated at room temperature for 6 hours, pur-
ified through Amicon 100 kDa molecular-weight cutoff
centrifugal filters, and buffer exchanged into PBS (pH 7.4).
The number of NOTA cages per mAb was calculated by the
isotopic dilution method and was found to be approximately
0.543 (see Table S1 online version only).
Radiolabeling
64CuCl2 was diluted 50:50 in ammonium acetate buffer (pH
5.5) when received. EphA2-4B3-NOTA (150 mg) in ammo-
nium acetate buffer (pH 5.5) was added to a solution of
64CuOAc (100 MBq) in ammonium acetate buffer (pH 5.5)
and stirred at room temperature for 1 hour. A 10 mL aliquot
of the reaction was removed, added to a large excess of
ethylenediaminetetraacetic acid (EDTA; 1,000:1 molar
excess), stirred at room temperature for 30 minutes, and
spotted onto thin-layer chromatography (TLC) paper. Fol-
lowing TLC in a 50:50 EtOH:ammonium acetate eluent
system, > 95% 64Cu binding was found by radioisotopic
imaging of the TLC plate using a Bruker MSFX Pro (Bruker,
Billerica, MA), and the final product was obtained with a
specific activity of 581 MBq/mg. The TLC plate was subse-
quently cut into two sections (Retention factor [Rf] > 0.3 and
Rf < 0.3), and the total gamma emissions were counted
using a PerkinElmer 2480 Automatic Gamma Counter
(PerkinElmer, Waltman, MA) to confirm > 95% labeling
efficiency (see Figure S2 and Table S2, online version only).
The resulting EphA2-4B3-NOTA-64Cu was used without
further purification. The stability of EphA2-4B3-NOTA-64Cu
was evaluated by incubation in PBS and fetal bovine serum
(FBS) at 37 for 24 hours followed by analysis by instant TLC
(see Figure S3 and Table S3, online version only).
PET/MRI Acquisition
All animal experiments were approved by The University of
Queensland Animal Ethics Committee and QIMR-B Animal
Ethics Committee. Mice were injected with EphA2-4B3-
NOTA-64Cu (5–7 MBq) intravenously via the lateral tail vein
under isoflurane anesthesia.Miceweremaintained under 1 to
2% isoflurane in anair-oxygenmixture at a flow rateof 2 L/min
for the duration of the imaging session and monitored by
a breathing pillow. At 0, 6, and 22 hours following
injection, mice were positioned on the scanner bed (Bru-
ker 7T Clinscan interfaced with a Siemens Spectrometer
running Numaris/4 VB17 with a PET ring centered at the
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isocenter of the magnet consisting of three rings of 16
crystal blocks),44 and two T1-weighted images were acquired
using a three-dimensional (3D) gradient echo sequence
(repetition time = 12 ms; echo time = 1.07 ms; field of view
= 105  39  28 mm; acquisition matrix = 416  156 
112; slice partial Fourier = 6/8; number of averages = 6;
total acquisition time = 14 minutes). A 30-minute PET
static emission scan was acquired simultaneously with the
MRI acquisition. PET images were reconstructed by a two-
dimensional ordered subsets expectation maximum
(OSEM2D) algorithm with no attenuation or scatter cor-
rection. A third T1-weighted 3D GE image, using a pulse
angle of 21, was acquired following intravenous injection
of Magnevist (Bayer HealthCare, Whippany, NJ) (50 mL) via
the lateral tail vein at 22 hours postinjection. Images were
brought into the same stereotactic space, registered by rigid
transformations only, and analyzed using Inveon Research
Workplace (IRW) software version 4.1 (Siemens).
Image Analysis
For each PET image, 3D region of interest (ROIs) were
drawn over the tumor and other organs of interest guided by
the MRI using the IRW 4.1 software. Activity per voxel was
converted to Bq/mL using a conversion factor obtained by
scanning a cylindrical phantom filled with a known activity
of 64Cu to account for PET scanner efficiency. Activity
concentration in the ROI was calculated as the mean Bq/mL
multiplied by the mass of the ROI assuming a tissue density
of 1 g/cc and was decay corrected to the time of injection.
Radioactivity in ROIs is presented as %ID/g (mean ± SD,
n = 3). The injected dose was calculated from the first image
as the mean activity in a ROI of the entire mouse divided by
the area of that ROI. The ROI was drawn using a thresh-
olding algorithm (IRW 4.1) to include all voxels with an
activity greater than background and removing islands
formed within the outline of the mouse. Tumor to brain
contrast was measured as the ratio of activity in two ROI,
one drawn around the tumor mass delineated by the
hyperintense region in the gadolinium (Gd) contrast–
enhanced MRI and a second ROI of equal volume placed in a
contralateral, nontumor region of brain.
Biodistribution Studies
Mice were injected with EphA2-4B3-NOTA-64Cu (2-3 MBq)
intravenously via the lateral tail vein and housed individually
for the duration of the experiment. Mice were anesthetized
with isoflurane at 24 hours postinjection and sacrificed by
exsanguination. Blood was sampled immediately following
sacrifice, and organs were harvested, cleaned of excess blood,
and weighed. Radioactivity in tissue was counted using
a PerkinElmer 2480 Automatic Gamma Counter and pre-
sented as %ID/g (mean ± SD, n = 3). The injected dose was
calculated from the radioactivity counted in a 10 mL sample
of the injected dose.
Results and Discussion
Specific Binding of EphA2-4B3 and EphA2-4B3-NOTA
to EphA2
To ensure that the binding affinity of EphA2-4B3 is not
altered significantly by NOTA conjugation, binding affinity
of EphA2-4B3 and EphA2-4B3-NOTAwas measured using a
Biacore T200 (GE Healthcare, Buckinghamshire, UK) with a
CM5 chip type. Both antibodies were captured to the same
level using a mouse IgG capture kit (GE Healthcare,
Buckinghamshire, UK) immobilized using amine coupling
to 12000RU. Binding affinity was measured using a single-
cycle-kinetics protocol with an HBS-EP+ running buffer
(GE Healthcare, Buckinghamshire, UK) at a flow rate of 40
mL/min. It was found that there was no significant difference
in binding affinity on conjugation of NOTA (see Figure S4
and Table S4, online version only).
PET/MRI, Biodistribution, and Comparative Tumor to
Brain Contrast of EphA2-4B3-NOTA-64Cu in a U87
Xenograft Model of Glioblastoma
To investigate the efficacy of an EphA2 mAb as an imaging
agent for glioblastoma, we synthesized a conjugate of the mAb
(EphA2-4B3) with a multidentate ligand system to bind 64Cu.
The ligand system used was 1,4,7-triazacyclononane-1,4,7-
triacetic acid (NOTA), which was conjugated to the mAb via
reaction of primary amines on the mAb with an iso-
thiocyanate group covalently bound to the NOTA moiety. It
has previously been shown that mAb-NOTA-64Cu conjugates
show good stability in vivo.45–47 The purified EphA2-4B3-
NOTA conjugate was complexed with 64Cu to form the PET
tracer EphA2-4B3-NOTA-64Cu.
To investigate the efficacy of EphA2-4B3-NOTA-64Cu, a
longitudinal PET/MRI study was conducted using a U87
xenograft model of glioblastoma (Figure 1). Following
intravenous injection, mice were imaged immediately with
further imaging sessions 6 and 22 hours postinjection. Full-
body biodistribution and pharmacokinetics of the tracer
were evaluated by ROI analysis and tumor to brain contrast
was measured at 6 hours postinjection, in the 18F-FDOPA
image and in the Gd contrast–enhanced MRI. At early time
points, a large proportion of the tracer is in the blood pool,
as can be evidenced by an ROI drawn around the heart in the
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image. The loss of tracer in the heart follows a single expo-
nential trend indicating minimal retention in cardiac tissue
through either specific or nonspecific binding. Uptake in the
lungs and kidneys follows the same single exponential trend
indicating that (1) tracer presence in these organs is likely
due to continued circulation in the bloodstream and
(2) clearance of the tracer is not likely to be via renal path-
ways. Tracer activity in the liver does not follow the same
trend as in the heart, and it can be seen that there is sig-
nificant retention of the tracer in the liver. Similarly, tracer
concentration in the spleen increases from 0 to 22 hours. We
suggest that retention of the tracer in both the liver and the
spleen is due to nonspecific binding by Fc receptors and
clearance through the reticuloendothelial system. Tracer
concentration at the tumor site increases from 0 to 6 hours
(4.03 ± 0.6–8.9 ± 1 %ID/g, n = 3) and decreases from 6 to 22
hours (8.9 ± 1–6.3 ± 0.9 %ID/g, n = 3). It can be seen that
delineation of the tumor boundaries is clear compared to
an 18F-FDOPA PET/MRI, a Gd contrast–enhanced MRI, and
a high-resolution T2-weighted MRI of the same mouse.
For the purpose of an imaging agent, the concentration of
tracer at the site of interest should be high enough to be clearly
distinguished from the background. In contrast to a ther-
apeutic agent, accumulation in organs that are far from the site
of interest will not affect the performance of the imaging agent
as this will not affect imaging contrast. In this case, although
accumulation of tracer in the liver and spleen is high, it does
not affect tumor to brain contrast. It can be seen (see Figure
1D) that tumor to brain contrast is significantly higher than
that in the 18F-FDOPA image (p < .01, two-tailed t-test) and is
higher than that in the Gd contrast–enhanced MRI.
PET/MRI Imaging, Biodistribution, and Tumor to
Brain Contrast of EphA2-4B3-NOTA-64Cu in RN1 and
WK1 Xenograft Models of Glioblastoma
The U87 model of glioblastoma is a useful model for pre-
clinical studies as it produces a reproducible, fast-growing,
and predictable tumor mass. However, there are problems
with how representative this model is compared to the
highly infiltrative tumors observed in most patients with
glioblastoma.40 To further investigate the efficacy of EphA2-
4B3-NOTA-64Cu as an imaging agent for glioblastoma,
a longitudinal PET/MRI study was conducted using RN1
(Figure 2) and WK1 (Figure 3) xenograft models of glio-
blastoma. Both of these cell lines more closely resemble the
disease in humans than the U87 model.
Similar to the U87 model, at early time points, the tracer
is predominantly in the blood pool for the RN1 and WK1
models. Again, the loss of tracer from the blood pool follows
Figure 1. PET-MRI and biodistribution of EphA2-4B3-NOTA-64Cu in a U87 xenograft model of glioblastoma. A, Representative maximum
intensity projection image of a female NOD/SCID mouse with a xenograft of 105 U87 cells injected into the right striatum 22 hours following
injection of the PET tracer EphA2-4B3-NOTA-64Cu. B, Representative images of the brain of a female NOD/SCIDmouse with a xenograft of 105 U87
cells injected into the right striatum at 0, 6, and 22 hours postinjection (p.i.) of the PET tracer. C, Region of interest (ROI) analysis of images at 0, 6,
and 22 hours p.i. Values are represented as mean ± standard deviation (n = 3). D, Tumor to brain contrast as measured by ROI analysis of a tumor
ROI and contralateral brain ROI. Values are represented as mean ± standard deviation (n = 3). E, [18F]FDOPA image of the same mouse 24 hours
prior to EphA2-4B3-NOTA-64Cu imaging. F, Gadolinium contrast–enhanced MRI of the same mouse 22 hours p.i. G, High-resolution T2-weighted
MRI of the same mouse 24 hours prior to EphA2-4B3-NOTA-64Cu imaging.
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a single exponential and tracer concentration in the lungs
and kidneys follows the same trend. Again, as observed with
the U87 model, tracer accumulation in the liver and spleen is
observed, and we suggest that the same mechanism of
nonspecific binding through Fc receptors and clearance
through the reticuloendothelial system is responsible. Con-
centration of the tracer at the tumor site peaks after 6 hours
(RN1 = 3.8 ± 1.1 %ID/g, n = 3; WK1 = 10.2 ± 2.1 %ID/g, n
= 3) and decreases after 22 hours (RN1 = 2.9 ± 0.7 %ID/g, n
= 3; WK1 = 8.2 ± 1.9 %ID/g, n = 3). It can be seen that
unlike the U87 model, the tumor is not as homogeneous in
shape; however, delineation of the tumor boundaries is clear
compared to an [18F]FDOPA PET/MR image, a Gd
contrast–enhanced MRI, and a high-resolution T2-weighted
MRI of the same mouse. In both cases, tumor to brain
contrast is significantly higher than that in the [18F]FDOPA
image (RN1 p < .01, WK1 p < .001, two-tailed t-test) and
that in the Gd contrast–enhanced MRI (RN1 p < .05, WK1
p < .01, two-tailed t-test).
Of particular interest is comparison between [18F]
FDOPA, Gd MRI, and EphA2-4B3-NOTA-64Cu imaging
in the WK1 model of glioblastoma. It can be seen (see
Figure 3H) that enhancement in the Gd MRI is unclear and
results in a potentially blurred delineation of tumor
boundaries. Similarly, the low tumor to brain contrast in the
[18F]FDOPA image could lead to a misinterpretation of
tumor boundaries. In contrast, the boundaries delineated by
EphA2-4B3-NOTA-64Cu are more pronounced and correlate
well with hematoxylin-eosin–stained histology.
PET/MRI Imaging and Biodistribution of EphA2-
4B3-NOTA-64Cu in a U87 Xenograft Model When
Nonspecific Binding is Blocked
For a brain tumor imaging agent, accumulation in organs that
are not anatomically close to the site of interest is of minimal
concern with respect to image contrast. However, to further
investigate the potential of an EphA2-specific mAb as a tar-
geted therapeutic, we conducted investigations into the spe-
cificity of binding in the liver and spleen. We propose that
accumulation of the EphA2-4B3-NOTA-64Cu tracer in the
liver and spleen is due to nonspecific binding by Fc receptors.
NOD/SCID mice do not naturally express IgG. As such, there
is no natural IgG in the bloodstream to reduce the number of
vacant Fc receptors in the liver and spleen of these mice. We
postulate that the high uptake of the PET tracer EphA2-4B3-
NOTA-64Cu in the liver and spleen will be greatly reduced if
injected into immunocompetent mice such as a C57Bl/6. To
further investigate this, a longitudinal PET/MRI study and an
ex vivo biodistribution study were conducted to compare the
Figure 2. EphA2-4B3 targets an RN1 primary line xenograft model of glioblastoma. A, Representative maximum intensity projection image of a
female NOD/SCID mouse with a xenograft of 105 RN1 cells injected into the right striatum 22 hours following injection of the PET tracer EphA2-
4B3-NOTA-64Cu. B, Representative images of the brain of a female NOD/SCID mouse with a xenograft of 105 RN1 cells injected into the right
striatum at 0, 6, and 22 hours postinjection (p.i.) of the PET tracer. C, Region of interest (ROI) analysis of images at 0, 6, and 22 hours p.i. Values are
represented as mean ± standard deviation (n = 3). D, Tumor to brain contrast as measured by ROI analysis of a tumor ROI and contralateral brain
ROI. Values are represented as mean ± standard deviation (n = 3). E, [18F]FDOPA image of the same mouse 24 hours prior to EphA2-4B3-
NOTA-64Cu imaging. F, Gadolinium contrast–enhanced MRI of the same mouse 22 hours p.i. G, High-resolution T2-weighted MRI of the same
mouse 24 hours prior to EphA2-4B3-NOTA-64Cu imaging.
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two models. It can be seen from Figure 4 that there is a stark
contrast between the two mice. The maximum intensity
projection image at 22 hours (see Figure 4A) shows that the
majority of the activity is in the liver and spleen of the NOD/
SCIDmouse, whereas the majority of activity is in the heart of
the C57Bl/6 mouse. This is corroborated by the ex vivo bio-
distribution data 24 hours postinjection (see Figure 4B),
where it can be seen that in C57Bl/6 mice, there is more
activity in the blood than in any other organ and significantly
more than in NOD/SCID mice (C57Bl/6 = 3.1 ± 1.3 %ID/g,
n = 3; NOD/SCID = 0.08 ± 0.008 %ID/g, n = 3; p = .03) and
significantly less activity in the spleen (C57Bl/6 = 2.3 ± 1 %
ID/g, n = 3; NOD/SCID = 14.4± 1.1 %ID/g, n = 3; p = .0003).
Furthermore, dynamic analysis of the image data (see
Figure 4C) shows the stark difference in the removal of tracer
from the blood pool in the two models.
Given the difference between the C57Bl/6 and NOD/
SCID model, a longitudinal PET/MRI study was conducted
using a U87 xenograft model of glioblastoma in NOD/SCID
mice in which the mice received a 1 mg dose of nonspecific
IgG intravenously 30 minutes prior to injection of the tracer.
This was intended to block Fc receptors and simulate the
situation in the C57Bl/6 mouse (Figure 5) without saturating
EphA2 receptors in the tumor. The technique of predosing
with a bolus of cold tracer has been shown to increase uptake
into the tumor when using antibody-based tracers.48,49
However, when using this technique, there is an inherent
danger that the targeted receptor sites in the tumor could be
blocked if the cold predose is too high. To circumvent this,
we used a cold predose of a nonspecific IgG that should bind
to Fc receptors, thus reducing the number of receptors
available to bind the tracer but leave the targeted EphA2
receptors free.
As can be seen in Figure 5C, at early time points, the
tracer is again predominantly in the blood pool. The loss of
tracer from the blood follows an exponential trend (as
Figure 3. EphA2-4B3 targets a WK1 primary line xenograft model of glioblastoma. A, Representative maximum intensity projection image of a
female NOD/SCID mouse with a xenograft of 105 WK1 cells injected into the right striatum 22 hours following injection of the PET tracer EphA2-
4B3-NOTA-64Cu. B, Representative images of the brain of a female NOD/SCID mouse with a xenograft of 105 WK1cells injected into the right
striatum at 0, 6, and 22 hours postinjection (p.i.) of the PET tracer. C, Region of interest (ROI) analysis of images at 0, 6, and 22 hours p.i. Values are
represented as mean ± standard deviation (n = 3). D, Tumor to brain contrast as measured by ROI analysis of a tumor ROI and contralateral brain
ROI. Values are represented as mean ± standard deviation (n = 3). E, [18F]FDOPA image of the same mouse 24 hours prior to EphA2-4B3-
NOTA-64Cu imaging. F, Gadolinium contrast–enhanced MRI of the same mouse 22 hours p.i. G, High-resolution T2-weighted MRI of the same
mouse 24 hours prior to EphA2-4B3-NOTA-64Cu imaging. H, Comparative slices showing tumor contrast by hematoxylin-eosin (H&E)-stained
histology, gadolinium contrast–enhanced MRI, and EphA2-4B3-NOTA-64Cu and [18F]FDOPA imaging. The same window level has been applied to
the EphA2-4B3-NOTA-64Cu image and the [18F]FDOPA image to illustrate tumor to brain contrast.
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Figure 5. Blocking nonspecific binding increases tumor accumulation. A, Representative maximum intensity projection image of a female NOD/
SCID mouse with a xenograft of 105 U87 cells injected into the right striatum 22 hours following injection of the PET tracer EphA2-4B3-NOTA-64Cu
where 1 mg nonspecific IgG had been administered intravenously 2 hours prior to injection of the tracer. B, Representative images of the brain of a
female NOD/SCID mouse with a xenograft of 105 U87 cells injected into the right striatum at 0, 6, and 22 hours postinjection (p.i.) of the PET tracer
EphA2-4B3-NOTA-64Cu where 1 mg nonspecific IgG had been administered intravenously 2 hours prior to injection of the tracer. C, Region of
interest (ROI) analysis of images at 0, 6, and 22 hours p.i. (n = 3). D, [18F]FDOPA image of the same mouse 24 hours prior to EphA2-4B3-
NOTA-64Cu imaging. E, Gadolinium contrast–enhanced MRI of the same mouse 22 hours p.i. F, High-resolution T2-weighted MRI of the same
mouse 24 hours prior to EphA2-4B3-NOTA-64Cu imaging.
Figure 4. A, Representative maximum intensity projection images of a 12-week-old female C57Bl/6 mouse and a 12-week-old female NOD/SCID
mouse 22 hours following intravenous injection of the PET tracer EphA2-4B3-NOTA-64Cu. It is clear that the tracer remains in the bloodstream in
the C57Bl/6 mouse far longer than in the NOD/SCID mouse. B, Comparative biodistribution of EphA2-4B3-NOTA-64Cu in C57Bl/6 and NOD/
SCID mice 22 hours following intravenous injection. C, Time-activity curves of regions of interest drawn over the heart of C57Bl/6 and NOD/SCID
mouse images. The first 30 minutes following intravenous injection of EphA2-4B3-NOTA-64Cu are displayed.
Puttick et al392
evidenced by the loss of activity in the heart). The loss of
tracer from the lungs and kidneys again follows the same
trend as the heart. In addition, and in contradiction to the
U87 model without a blocking dose, the loss of tracer from
the liver shows the same trend, and accumulation in the
spleen is significantly reduced. It can be seen that by 22
hours, tracer concentration in both the liver (U87 block =
18.6 ± 2.1 %ID/g, n = 3; U87 = 22.4 ± 1.2 %ID/g, n = 3;
p = .06, paired, two-tailed t-test) and spleen (U87 block =
14.5 ± 2.9 %ID/g, n = 3; U87 = 24.2 ± 1.2 %ID/g, n = 3;
p = .02, paired, two-tailed t-test) is significantly lower than
that in the U87 model without a blocking dose. In addition,
tracer concentration in the tumor is significantly increased
by 22 hours (U87 block = 26.7 ± 6.5 %ID/g, n = 3; U87 = 6.3
± 0.9 %ID/g, n = 3; p = .04, paired, two-tailed t-test) and is
greater than that in any other organ (see Figure 5 and
Figure 6). We propose that this is due to increased circula-
tion times as nonspecific binding, and subsequent removal
of the tracer from the blood pool, has been blocked. It can be
seen that when a blocking dose of nonspecific IgG is
administered, delineation of the tumor by EphA2-4B3-
NOTA-64Cu is very pronounced.
Conclusions
There is growing interest in improving image-guided ther-
apy for patients with glioblastoma. PET imaging with highly
specific mAbs conjugated to radiometals with a long half-life
offers significant clinical potential. Such tracers not only
specifically target cancer cells but can also be transported to
clinical sites without access to cyclotron and radiopharmacy
facilities. This is a significant benefit in a country with a
widely spread population such as Australia. In this study, we
describe for the first time the efficacy of EphA2-4B3-
NOTA-64Cu as a PET tracer for delineating the boundaries of
a tumor in glioblastoma compared to the current clinical
standards of [18F]FDOPA PET and Gd contrast–enhanced
MRI in an intracranial model of glioblastoma. PET/MRI of
EphA2-4B3-NOTA-64Cu in U87, RN1, and WK1 models of
glioblastoma showed high tumor uptake and higher tumor
to brain contrast than both [18F]FDOPA PET and Gd
contrast–enhanced MRI. Tumor delineation in all models
was also excellent compared to the current clinical standards
of [18F]FDOPA PET imaging, Gd contrast–enhanced MRI,
and T2-weighted MRI. We showed that high uptake of the
tracer in the liver and spleen is significantly reduced in a
mouse model that expresses natural IgG and that high liver
and spleen uptake can be effectively reduced by adminis-
tration of a blocking dose of nonspecific IgG. In addition, we
showed that tumor uptake can be increased by administra-
tion of a blocking dose of nonspecific IgG. To our knowl-
edge, this is the first report of enhanced tumor uptake by the
addition of a nonspecific mAb designed to block Fc recep-
tors. Following this work, we suggest that future clinical
development of the use of EphA2-4B3-NOTA-64Cu as an
imaging agent for glioblastoma is warranted.
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EphA2 as a Diagnostic Imaging Target in Glioblastoma:
A Positron Emission Tomography/Magnetic Resonance
Imaging Study
Simon Puttick, Brett W. Stringer, Bryan W. Day, Zara C. Bruce, Kathleen S. Ensbey, Karine Mardon, Gary J. Cowin,
Kristofer J. Thurecht, Andrew K. Whittaker, Michael Fay, Andrew W. Boyd, and Stephen Rose
Expression of EphA2 in U87, RN1, and WK1 Cell Lines
E xpression of the EphA2 target was confirmed in U87,RN1, and WK1 cell lines by flow cytometry. Cells were
trypsinized from adherent cultures by incubating with 0.25%
trypsin and 50mMethylenediaminetetraacetic acid (EDTA) in
phosphate-buffered saline (PBS) to give single cell suspen-
sions. Cell suspensions were incubated with an anti-EphA2
monoclonal antibody (mAb) or an isotype IgG1 control at
5 mg/mL on ice for 20 minutes in PBS with 10% fetal bovine
serum and washed three times with PBS. The cells were further
incubated with a secondary, phycoerythrin (PE)-conjugated
goat antimouse antibody (Dako, 1:100) for 20 minutes on ice.
Cells were washed three times with PBS and run through a BD
LSRFortessa flow cytometer (BC Biosciences, Franklin Lakes,
NJ). Figure S1 shows histograms of fluorescence counts at the
wavelength of PE emission; it can be seen that EphA2 is highly
expressed in all cell lines used in this study.
Calculation of the Number of NOTA Cages per mAb
NOTA-NCS (100 mg) was dissolved in sodium carbonate
buffer (pH 9) and added to EphA2-4B3 (1 mL at 1 mg/mL)
in sodium carbonate buffer (pH 9). The resulting mixture
was gently agitated at room temperature for 6 hours, pur-
ified through Amicon 100 kDa molecular-weight cutoff
centrifugal filters, and buffer exchanged into PBS (pH 7.4).
The number of NOTA cages per mAb was calculated by the
isotopic dilution method and was found to be approximately
0.51; 0.1 mg EphA2-4B3-NOTA in ammonium acetate buffer
(pH 5.5) was added to a solution of 64CuOAc (10 MBq) and
stirred at room temperature for 1 hour. The solution was
added to a large excess of EDTA (1,000:1 molar excess),
stirred at room temperature for 30 minutes, and spotted
onto thin-layer chromatography (TLC) paper. Following
TLC in a 50:50 EtOH:ammonium actetate eluent system, the
TLC plate was cut into two (Retention factor [Rf] > 0.3 and
Rf < 0.3), and the total gamma emissions were counted using
a PerkinElmer 2040 Automatic Gamma Counter. Counts per
minute (CPM) values were decay corrected back to the time
of the first measurement. The number of NOTA cages was
calculated using the following equation:
No:NOTA ¼
moles Cu 
h cpm Rf < 0:3 
cpm totalð Þ
i 
moles mAb
Validation of Labeling Efficiency
64CuCl2 was diluted 50:50 in ammonium acetate buffer
(pH 5.5) when received. EphA2-4B3-NOTA (150 mg) in
ammonium acetate buffer (pH 5.5) was added to a solution
of 64CuOAc (100 MBq) in ammonium acetate buffer (pH
5.5) and stirred at room temperature for 1 hour. A 10 mL
aliquot of the reaction was removed, added to a large excess
of EDTA (1,000:1 molar excess), stirred at room tempera-
ture for 30 minutes, and spotted onto TLC paper. Following
TLC in a 50:50 EtOH:ammonium acetate eluent system
> 95%, 64Cu binding was found by radioisotopic imaging
of the TLC plate (Bru¨ker MSFX Pro). The TLC plate was
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subsequently cut into two sections (Rf > 0.3 and Rf < 0.3),
and the total gamma emissions were counted using a Per-
kinElmer 2480 Automatic Gamma Counter to confirm
> 95% labeling efficiency.
Specific Binding of EphA2-4B3 and EphA2-4B3-NOTA
to EphA2
To ensure that the binding affinity of EphA2-4B3 is not altered
significantly by NOTA conjugation, binding affinity of EphA2-
4B3 and EphA2-4B3-NOTA was measured using a Biacore
T200 with a CM5 chip type. Both antibodies were captured to
the same level using a mouse IgG capture kit (GE Healthcare,
Buckinghamshire, UK) immobilized using amine coupling to
12,000 RU. Binding affinity was measured using a single-cycle-
kinetics protocol with an HBS-EP+ running buffer (GE) at a
flow rate of 40 mL/min. The data were fitted to a 1:1 Langmuir
binding model, and it was found that there was no significant
difference in binding affinity on conjugation of NOTA.
Reference
1. Meares CF, McCall MJ, Reardan DT, et al. Conjugation of
antibodies with bifunctional chelating-agents - isothiocyanate and
bromoacetamide reagents, methods of analysis, and subsequent
addition of metal-ions. Anal Biochem 1984;142:68–78.
Figure S1. Fluorescence-activated cell sorting (FACS) data showing expression of EphA2 in the three cell lines used in this study. It can be seen that
the receptor is highly expressed in all cell lines.
Figure S2. a) Radiographic image of a TLC plate used to test radiolabeling efficiency. b) Line profile of lane 2 (64CuOAc). c) Lane profile of lane 1
(EphA2-4B3-NOTA-64Cu).
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Figure S3. Instant TLC analysis of the stability of EphA2-4B3-NOTA-64Cu. Traces are normalized to the intensity of the EphA2-4B3-NOTA-64Cu
peak for ease of interpretation.
Table S1. Number of NOTA Cages per mAb as Calculated by Isotopic Dilution
Experiment No. moles mAb No. moles 64Cu CPM (Rf > 0.3) CPM (Rf < 0.3) No. NOTA
1 6.66  10–13 1.1  10–12 497838.55 206847.12 0.48
2 6.66  10–13 1.1  10–12 530724.69 243600.12 0.52
3 6.66  10–13 1.1  10–12 516230.07 221101.90 0.49
CPM = counts per minute; mAb = monoclonal antibody; Rf = Retention factor.
Figure S4. Reference flow cell subtracted sensorgrams and binding model fits for a single-cycle-kinetics SPR protocol of EphA2-4B3 and
EphA2-4B3-NOTA.
Puttick et al398
Table S4. Association Rate Constant (ka), Dissociation Rate Constant (kd), and Affinity Constant (KD) of EphA2-4B3 and
EphA2-4B3-NOTA
Sample ka (1/ms) kd (1/s) KD (M) 2
EphA2-4B3 6.18  104 2.36  10–4 3.82  10–9 0.062
EphA2-4B3-NOTA 6.11  104 2.33  10–4 3.81  10–9 0.087
It can be seen that there is no significant change in binding on conjugation of NOTA.
Table S3. Peak Fitting Analysis of iTLC Traces
Sample Peak RF Peak Assignment Peak Area (CPM) Relative Area (%)
PBS incubation 0.13 EphA2-4B3-NOTA-64Cu 3.73E6 0.88
PBS incubation 0.21 Other 0 0
PBS incubation 0.75–0.9 64CuOAc 5.29E5 0.12
FBS incubation 0.13 EphA2-4B3-NOTA-64Cu 3.47E6 0.73
FBS incubation 0.21 Other 8.34E5 0.17
FBS incubation 0.75–0.9 64CuOAc 4.76E5 0.10
CPM = counts per minute; FBS = fetal bovine serum; iTLC = instant thin-layer chromatography; PBS = phosphate-buffered saline; Rf = Retention factor.
Peaks were fit to a gaussian distribution using Origin Pro 8.6 (OriginLab, Northampton, MA).
Table S2. Validation of Labeling Efficiency by Gamma Counting
CPM (Rf < 0.3) CPM (Rf > 0.3) Labeling Efficiency
185798.25 7163.58 96.3%
CPM = counts per minute; Rf = Retention factor.
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